DECA · Denali Capital Acquisition Corp. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | $50.00M | - | - | $50.00M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $1.27M | - | $1.14M | - | - | - | - | - | - | - |
| SG&A | $3.31M | - | $1.06M | - | - | - | - | - | - | - |
| Total Operating Expenses | $665.0K | - | $1.30M | $374.9K | $246.6K | - | $213.0K | $168.2K | $368.3K | - |
| D&A | $0 | - | $0 | - | - | - | - | - | - | - |
| Operating Income | ($4.58M) | - | ($152.59M) | ($374.9K) | ($368.3K) | - | ($213.0K) | ($168.2K) | - | - |
| Interest Expense | - | - | - | $23.1K | $27.0K | - | $25.2K | - | $21.3K | $100.0K |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($4.58M) | - | ($152.59M) | ($385.1K) | ($194.6K) | - | ($40.9K) | $448.9K | $264.3K | - |
| EPS - Basic | ($0.01) | - | ($0.01) | - | - | - | - | - | - | - |
| EPS - Diluted | ($0.02) | - | ($0.76) | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $103.0K | $20.0K | $12.0K | $126 | $2.7K | $16.9K | $14.3K | $1.5K | $1.0K | $204.5K |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $6.42M | $5.91M | $4.29M | - | - | - | - | - | - | - |
| Current Assets | $1.22M | $596.0K | $85.0K | $14.1K | $2.7K | $16.9K | $35.4K | $43.8K | $65.4K | $209.4K |
| Total Assets | $1.97M | $1.35M | $774.0K | $562.5K | $9.15M | $9.04M | $8.92M | $52.12M | $51.35M | $50.69M |
| Current Liabilities | $10.38M | $10.17M | $10.03M | $8.27M | $7.85M | $7.55M | $6.59M | $6.32M | $6.00M | $5.60M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $27.30M | $22.10M | $15.37M | $11.16M | $10.74M | $10.43M | $9.48M | $9.21M | $8.89M | $8.49M |
| Stockholders' Equity | ($25.33M) | ($20.75M) | ($14.59M) | ($11.14M) | ($10.74M) | ($10.42M) | ($9.45M) | ($9.16M) | ($8.82M) | ($8.28M) |
| Retained Earnings | ($280.38M) | ($275.80M) | ($269.64M) | ($11.14M) | ($10.74M) | ($10.42M) | ($9.45M) | ($9.16M) | ($8.82M) | ($8.28M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($2.67M) | - | - | - | ($114.1K) | - | - | - | ($374.2K) | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | $2.75M | - | - | - | $100.0K | - | - | - | $170.7K | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | 0.5% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -232.4% | - | -19715.0% | -68.5% | -2.1% | - | -0.5% | 0.9% | 0.5% | - |
| Return on equity | 18.1% | - | 1045.7% | 3.5% | 1.8% | - | 0.4% | -4.9% | -3.0% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.12 | 0.06 | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.04 |
| Quick ratio | 0.12 | 0.06 | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.04 |
| Cash ratio | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | -16.3x | -13.7x | - | -8.5x | - | - | - |
| Equity multiplier | -0.08 | -0.06 | -0.05 | -0.05 | -0.85 | -0.87 | -0.94 | -5.69 | -5.82 | -6.12 |
| Liabilities / Assets | 13.86 | 16.42 | 19.85 | 19.84 | 1.17 | 1.15 | 1.06 | 0.18 | 0.17 | 0.17 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | 5.53 | - | - | 0.97 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -1142.6% | - | -71556.9% | -122.9% | - | - | - | - | - | - |
| Net income growth (YoY) | -2251.5% | - | -373346.6% | - | - | - | - | -1.9% | - | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -135.9% | -99.2% | -54.5% | -21.6% | -21.7% | -25.8% | -19.1% | -39.1% | -69.9% | -153.2% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Denali Capital Acquisition Corp. against the 5 most active filers in the same SIC group.